Imiglucerase - Biologic Drug Details

Summary for imiglucerase

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for imiglucerase

Recent Clinical Trials for imiglucerase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
AVROBIO	Phase 2/Phase 3
Sanofi	Phase 4
ISU Abxis Co., Ltd.	Phase 1

See all imiglucerase clinical trials

Pharmacology for imiglucerase

Established Pharmacologic Class	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Chemical Structure	Glucosylceramidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for imiglucerase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for imiglucerase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2011-08-21	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2013-06-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for imiglucerase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2036-12-20	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2036-07-29	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2033-11-19	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2037-12-26	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2038-12-19	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2038-06-21	Patent claims search

International Patents for imiglucerase

Country	Patent Number	Estimated Expiration
Germany	68926569
Japan	H03503721
European Patent Office	0401362
Canada	2006709
Japan	2893481
Japan	H03502289

Market Dynamics and Financial Trajectory for Imiglucerase

Last updated: February 21, 2026

What Is Imiglucerase?

Imiglucerase is a recombinant enzyme used for enzyme replacement therapy (ERT) in patients with Gaucher disease, a rare inherited disorder caused by deficient beta-glucocerebrosidase enzyme activity. It was developed by Genzyme, now a Sanofi subsidiary, and approved by the FDA in 1994. The drug's primary function is to reduce the accumulation of glucocerebroside in macrophages, alleviating symptoms like organomegaly, anemia, and bone crises.

What Are the Core Market Factors Influencing Imiglucerase?

Market Size and Patient Population

• Estimated global prevalence of Gaucher disease ranges between 1 in 40,000 and 1 in 100,000.
• Approximately 8,000 to 10,000 patients worldwide are eligible for treatment, with roughly 5,500 actively receiving ERT worldwide.
• The US accounts for over 50% of the treated population due to better diagnosis rates and accessibility.

Key Competitors

• Imiglucerase (Cerezyme): Market leader; produced by Sanofi.
• Velaglucerase alfa (Vpriv): Developed by Takeda.
• Taliglucerase alfa (Elelyso): Developed by Pfizer.

The introduction of Velaglucerase and Taliglucerase provided alternative options, impacting market share dynamics.

Pricing and Reimbursement

• Estimated annual treatment cost per patient ranges from $250,000 to $300,000.
• Reimbursement challenges vary by country; in the US, Medicare and private insurers cover most treatment costs.
• A shift toward biosimilars or generic enzyme products remains hindered by regulatory and manufacturing complexities.

Regulatory and Market Access Trends

• The drugs are under orphan drug status, ensuring market exclusivity in certain jurisdictions.
• Patent expirations for formulations are not imminent, with many patents extending into the late 2020s or early 2030s.
• Emerging data from real-world registries influence reimbursement policies.

How Do Market Trends Shape the Financial Trajectory?

Revenue Estimates and Historical Performance

• Sanofi reported approximately €1.2 billion (~$1.4 billion) annually from Cerezyme sales pre-2016.
• Industry estimates peg 2022 revenues at roughly $1.2 billion globally, with a declining trend due to market saturation and competition.

Revenue Drivers

• Patient growth: Limited expansion due to the rare disease status; increased diagnosis improves uptake.
• Pricing strategies: High-cost therapies support elevated revenue but face pressure amid reimbursement scrutiny.
• Patent protection: Ensures revenue streams until patent cliffs in the next decade.

Future Revenue Projections

Year	Estimated Revenue (USD millions)	Drivers
2023	1,200	Stable patient base, limited growth
2025	1,150	Patent protections, slow market penetration
2030	900	Patent expirations, biosimilar competition

Impact of Biosimilars and Market Entry Barriers

• No biosimilar approved yet for imiglucerase; biosimilar pathway is complex and costly.
• Regulatory delays and high manufacturing barriers limit biosimilar market entry.

Manufacturing and Supply Chain Factors

• Strict quality controls necessitate high manufacturing standards.
• Supply chain disruptions have historically impacted delivery and revenues.

What Are the Key Regulatory Developments?

• Orphan drug protections extend patent exclusivity and market advantage.
• Post-approval commitments focus on safety and efficacy monitoring.
• Accelerated pathways or designations have been influencing approval timelines for alternative therapies.

What Are the Investment and R&D Outlooks?

• Sanofi continues to invest in rare disease platforms, including gene therapy, which could alter imiglucerase's market position.
• Development of allogeneic hematopoietic stem cell-based treatments remains a comparative risk but potential disruptor.
• Efforts in improving enzyme manufacturing and delivery could extend patent life or reduce costs.

Summary of Market and Financial Outlook

• The market for imiglucerase remains stable but faces long-term decline prospects due to expiry of patents and biosimilar development.
• Revenue growth is constrained; high treatment costs sustain current levels but invite payer pressure.
• Innovation in alternative treatment approaches, such as gene therapy, could disrupt the market within the next decade.

Key Takeaways

• Imiglucerase remains the standard of care for Gaucher disease, with revenues primarily driven by existing patents and high treatment costs.
• Market growth is limited due to the small patient population and saturated market.
• Biosimilar competition is unlikely before late 2020s, given regulatory and manufacturing hurdles.
• Future revenue streams depend on patent protection, regulatory environment, and competition from emerging therapies.
• Strategic investments in R&D, particularly gene therapies, could reshape the market dynamics in the long term.

FAQs

1. When will patent expiration impact imiglucerase revenues?

Most patents are set to expire between 2025 and 2030, opening potential for biosimilar entry.

2. Are biosimilars likely to enter the market for imiglucerase?

Biosimilar development faces technical challenges and regulatory hurdles, delaying imminent market entry.

3. How does pricing influence the overall market?

High treatment costs bolster revenue but are subject to payer scrutiny, influencing market access and reimbursement policies.

4. What emerging therapies could challenge imiglucerase?

Gene therapies and alternative enzyme formulations are in development, potentially offering curative solutions or lower-cost options.

5. How are regulatory policies affecting future market prospects?

Orphan drug protections extend exclusivity, but policy changes or biosimilar approvals could accelerate market shifts.

---

References

1. Department of Health and Human Services. (2022). Gaucher Disease. Orphan Product Designation. https://www.fda.gov/

2. GlobalData. (2022). Gaucher Disease Market Analysis. https://www.globaldata.com/

3. Sanofi. (2023). Annual Report 2022. https://www.sanofi.com/

4. Shepherd, R. (2021). Biosimilar Development in Enzyme Replacement Therapies. Regulatory Toxicology and Pharmacology, 122, 104887.

5. European Medicines Agency. (2022). Human Medicines. Gaucher Disease. https://www.ema.europa.eu/